autoimmune disease Archives
Study identifies potential new approach for treating lupus
Jan. 13, 2023—A Vanderbilt study found that targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus — the most common form of the chronic autoimmune disease lupus.
VUMC to test whether Alzheimer’s drug can ease lupus symptoms
Oct. 6, 2022—Vanderbilt University Medical Center is partnering with Evergreen Therapeutics Inc. to test whether an Alzheimer’s drug, memantine, can improve cognitive symptoms associated with systemic lupus.
Study identifies key player in T cell “education”
Sep. 1, 2022—New Vanderbilt research could inform therapeutic strategies for enhancing thymic function when desired — such as during aging, recovery from radiation therapy or chemotherapy, or other conditions that reduce T cell output.
A new mechanism for lupus
Aug. 30, 2022—Vanderbilt researchers describe a new mechanism for the most common form of lupus and suggest a new treatment approach to this autoimmune disease.
COVID-associated bleeding risk
May. 5, 2022—While case reports have noted acquired hemophilia after COVID-19 infection or vaccination, a new study finds no increased risk.
Impaired neutrophils in autoimmunity
Jan. 27, 2022—Vanderbilt researchers help answer the question of why patients with autoimmune diseases like lupus are more susceptible to bacterial infections: their neutrophils have impaired antibacterial activity.
‘Pre-conditioning’ restores immune tolerance
Sep. 16, 2021—A treatment targeting T-cell metabolism could reinvigorate immune tolerance mechanisms to combat autoimmune disease and transplant rejection, Vanderbilt researchers discovered.
Autoimmunity advance
Aug. 24, 2021—Vanderbilt researchers have developed a high-throughput screening method to identify and characterize antigen-specific B cells — potential biomarkers for autoimmune disease and targets for new treatments.
Team studies new use for pulmonary hypertension drug
Mar. 25, 2021—An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered.
“Nur” target may aid arthritis treatment
Jul. 13, 2020—Vanderbilt immunologists have discovered that the protein Nur77 is part of a control mechanism that guards against autoimmunity in natural killer T cells.
Probing innate immunity
May. 19, 2020—Manuel Ascano team validates an inhibitor of the cGAS-STING signaling pathway, which is important for cellular innate immunity against bacteria, viruses, and our own damaged DNA.
Team’s findings show glutamine metabolism affects T cell signaling
Nov. 1, 2018—The cellular nutrient glutamine launches a metabolic signaling pathway that promotes the function of some immune system T cells and suppresses others, Vanderbilt researchers have discovered.
